ABT-737

目录号:S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737是一种BH3模拟抑制剂,作用于Bcl-xLBcl-2Bcl-w,无细胞试验中EC50分别为78.7 nM,30.3 nM和197.8 nM;但对Mcl-1, Bcl-B及Bfl-1没有抑制作用。Phase 2。

规格 价格 库存 购买数量  
RMB 3144.65 现货
RMB 972.14 现货
RMB 1647.36 现货
RMB 4659.22 现货
RMB 7964.03 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献92篇:

客户使用该产品的17个实验数据:

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

     

     

    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell Death Dis 2013 4, e801. ABT-737 purchased from Selleck.

    (B) The sensitivity (LD50) of CLL cells, assessed by annexin V staining after 48 h of treatment with ABT‐737, ABT‐263 or ABT‐199, was plotted against the pBcl‐2/Bcl‐2, Mcl‐1/Bcl‐2 and (pBcl‐2 + Mcl‐1)/Bcl‐2 ratios. Relative protein quantification was carried out with kodak carestream molecular imaging software and normalized to β‐actin. Spearman's correlation (r) and P values are shown. Data shown are representative of five independent experiments.

    Br J Pharmacol, 2016, 173(3):471-83. ABT-737 purchased from Selleck.

  • Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.
     

     

     

    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

    Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

     

     

    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

  • Effects of ABT-737 and RES, applied alone and in combination, on the viability of MOLT-4 cells.

    Toxicol In Vitro, 2017, 42:38-46. ABT-737 purchased from Selleck.

    Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

  • GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

    3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

     

     

    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

  • The combined use of ABT-737 and sorafenib changes the apoptotic effect. MC-3 cells were treated with the indicated compounds for 48 h. (A) Nuclear condensation and fragmentation were evaluated in DAPI-stained cells as described in the Materials and Methods (X400). (B) Live (green) and dead (red) cells were qualified using the Live/dead assay kit as described in the Materials and Methods (X200). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Arch Oral Biol, 2017, 73:1-6. ABT-737 purchased from Selleck.

    MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

     

     

    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

  • MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

产品安全说明书

Bcl-2抑制剂选择性比较

生物活性

产品描述 ABT-737是一种BH3模拟抑制剂,作用于Bcl-xLBcl-2Bcl-w,无细胞试验中EC50分别为78.7 nM,30.3 nM和197.8 nM;但对Mcl-1, Bcl-B及Bfl-1没有抑制作用。Phase 2。
特性 ABT-737是第一代抗凋亡BCL-2家族蛋白小分子抑制剂。
靶点
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
体外研究

ABT-737降低BCL-2/BAX异质二聚体,而诱导HL60细胞凋亡,但是对细胞周期分布没有抑制效果。ABT-737也诱导细胞色素C从线粒体中释放,促进BAX构象改变,BAX与凋亡相关。在白血病模型中,ABT-737按30 mg/kg处理,阻断53%白血病负荷,且使鼠寿命明显延长。ABT-737不会导致血细胞数和血清组成发生异常。[1]通过使Mcl-1失活而使抵抗细胞(Hela和MCF-7)对ABT-737敏感。当Mcl-1无效时,ABT-737也导致BAX/BAK-依赖的细胞色素C释放。ABT-737延长携带BCL-2肿瘤的鼠寿命。[2]ABT-737从BCL2’s BH3结合袋取代BIM,使BIM激活BAX,诱导线粒体透化作用,快速致死慢性淋巴细胞性白血病(CLL)细胞。[3] Noxa正向调节增强H196细胞对ABT-737敏感性。ABT-737抑制多种SCLC细胞系,包括NCI-H889, NCI-H1963, NCI-H1417, NCI-H146等的增殖,并诱导细胞凋亡。最近研究显示,ABT-737作用于ATLL细胞,明显诱导HTLV-1感染的T细胞凋亡。ABT-737按100 mg/kg剂量作用于ATLL鼠模型显示出强抗癌活性。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  NIT4[oRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MX:yOVAhdk4EoB?= NUP2O|REPzJiaB?= NXrSVWR7TE2VTx?= MonhZ4F2e2WmIEm3KUBtd3O|IH;mJJZq[WKrbHn0fUBqdiClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJGJEVDZic3nSUmE> NEThb3UzPjZ3N{K4PC=>
KG1a NU\5V|Z{S2WubDDWbYFjcWyrdImgRZN{[Xl? NVnyUZo2OC1zMDFOwG0> MnfINlQhcA>? NWD2[ItiTE2VTx?= NEjHZmJKSzVyPUeuOlgh|ryPLDDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXXHUWV3OjZ3NUK3NVI>
Kasumi-1 NY\LVYVwS2WubDDWbYFjcWyrdImgRZN{[Xl? MXOwMVExKM7:TR?= M4ThTlI1KGh? NHThSpVFVVOR NHTZUmdKSzVyPUSuPFch|ryPLDDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmHkNlY2PTJ5MUK=
KG1a MnLORZBweHSxc3nzJGF{e2G7 MXSwMVExKM7:TR?= NHTsN2IzPCCq MnrRSG1UVw>? NIjUW2tqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIfzOG4zPjV3MkexNi=>
Kasumi-1 NFvCTHBCeG:ydH;zbZMhSXO|YYm= Ml3ONE0yOCEQvF2= MWOyOEBp NIPhZlFFVVOR M1ftfIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYrLWWloOjZ3NUK3NVI>
MC-3  MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Xyc|UwOTBxMkCg{txO Mn\1NlQhcA>? MojkSG1UVw>? NYDVcZpQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVeyOlQ1PzZzNR?=
HN22  NVf2[Y9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTibYtXOi53L{euOU8zOi53IN88US=> NHXjU4IzPCCq NG[4e3FFVVOR NWH6Z3NvcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIrWWnczPjR2N{[xOS=>
MC-3  M3OybWFxd3C2b4Ppd{BCe3OjeR?= NUDjUFdzPS9zMD:yNEDPxE1? MXWyOEBp M1ywcGROW09? NEHHWolqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz Mnu1NlY1PDd4MUW=
HN22  MYHBdI9xfG:|aYOgRZN{[Xl? NHP6fIozNjVxNz61M|IzNjVizszN NHniU2YzPCCq MU\EUXNQ NGPGVYhqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz NX\FTopUOjZ2NEe2NVU>
MOLT-4 NEfjT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC0NVAuPTByMDDuUS=> NHnkb2c4OiCq MYPEUXNQ NV;EXFdVUUN3ME2wMlE6QCEQvF2= NGnNbIUzPjN7MkOzNi=>
RS4;11 NFzuWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fhVlExNTVyMECgcm0> NWrj[m5sPzJiaB?= M4nZVWROW09? MW\JR|UxRTBwMECyJO69VQ>? NX7rWZdmOjZ|OUKzN|I>
JURKAT MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[xNE02ODByIH7N M3jGUFczKGh? NH7zRXBFVVOR M2jmdWlEPTB;Nk[g{txO MWeyOlM6OjN|Mh?=
CEM R MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[xNE02ODByIH7N MnrvO|IhcA>? NGL0cGxFVVOR M1LuOGlEPTB;NT60JO69VQ>? M1\S[|I3Ozl{M{Oy
CEM S NIDuXGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT4NVAuPTByMDDuUS=> MlvVO|IhcA>? MUfEUXNQ M3nOTmlEPTB;MUKuNUDPxE1? NWfQcWNHOjZ|OUKzN|I>
MOLT-4 NHLB[GZCeG:ydH;zbZMhSXO|YYm= MnvtNVAuOTByMDDuUS=> NUS1b|lxOjRiaB?= M1TzUWROW09? M1nYe4NifXOnczD0bIUh[2ynYY\h[4Uhd2ZiQnPsMVIh[W6mIITo[UBld3ewcnXneYxifGmxbjDv[kBD[2xveFygZY5lKE2lbD2x NF7ldYgzPjN7MkOzNi=>
CEM S M4jkV2Fxd3C2b4Ppd{BCe3OjeR?= MmLxNVAuOTByMDDuUS=> MVSyOEBp MnXMSG1UVw>? MUjjZZV{\XNidHjlJINt\WG4YXflJI9nKEKlbD2yJIFv\CC2aHWg[I94dnKnZ4XsZZRqd25ib3[gRoNtNXiOIHHu[EBO[2xvMR?= M4T2dlI3Ozl{M{Oy
JURKAT Mle1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCxNFAuOTByMDDuUS=> M4G2RVQ5KGh? NI\RbZJFVVOR NGfIUphKSzVyPUm1OeKyQS5|IH7N Mn3GNlYyPzJ{Nkm=
LOUCY MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVSxNFAuOTByMDDuUS=> NHzUNII1QCCq M2rDUGROW09? NX;LNXUzUUN3ME2zNk45yrFzMD65JI5O M4jYVVI3OTd{Mk[5
WM-115 NVHBPIJNS2WubDDWbYFjcWyrdImgRZN{[Xl? NYXNNWpMOTBywrDuUS=> M2Tp[|czKGh? NF72cYZmdmijbnPld{BkfXKldX3pck1qdmS3Y3XkJIFvfGlvc4Xyeol3[W{EoB?= M{XsflI3OTF4N{e2
B16 NXzPTIJsS2WubDDWbYFjcWyrdImgRZN{[Xl? MVOxNFDDqG6P NX7xPI92PzJiaB?= NELTeZJmdmijbnPld{BkfXKldX3pck1qdmS3Y3XkJIFvfGlvc4Xyeol3[W{EoB?= MUiyOlEyPjd5Nh?=
HL-60  MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TpRlczKGh? NGrN[pZKSzVywrC9JFExNjdibl2= MkXVNlYxPDV4MEm=
MOLM-13  MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjmNXo4PzJiaB?= M3vJWmlEPTEEoE2gNlcvQSCwTR?= Mnm1NlYxPDV4MEm=
OCI-AML3 M3zSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXjO|IhcA>? NXHJ[ohEUUN3MNMgQUAyQTVyIH7N NXrMfGhnOjZyNEW2NFk>
BCWM.1 MlW1RZBweHSxc3nzJGF{e2G7 NGDmRlIxNTFwNjFOwG0> NHvPS2wzPCCq M3e2dYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MXmyOVg6OzJ7MB?=
MWCL-1 NGj2N|VCeG:ydH;zbZMhSXO|YYm= M2flZ|AuOS54IN88US=> NVryUlRGOjRiaB?= NXnpXWJWcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MleyNlU5QTN{OUC=
MM.1s MmjoRZBweHSxc3nzJGF{e2G7 Ml3INE0yNjZizszN MkK1NlQhcA>? NEfpV3BqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NEfHPGozPTh7M{K5NC=>
HCT116 NUPSPGhVTnWwY4Tpc44hSXO|YYm= MVGzM|ExKM7:TR?= MUCxNuKhcMLi MlnQSG1UVw>? M1jUTolv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckBNSzOELVnJJINwdn[ncoPpc44h[W6mIGPRV3ROOSCmZXfyZYRifGmxbh?= MmThNlU4OTVyMki=
HCT116 BAX BAK1 DKO NXHkTXR6TnWwY4Tpc44hSXO|YYm= NHXSNG8{NzFyIN88US=> MUGxNuKhcMLi MlnSSG1UVw>? M3zZ[olv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckBNSzOELVnJJINwdn[ncoPpc44h[W6mIGPRV3ROOSCmZXfyZYRifGmxbh?= NYCwTHlXOjV5MUWwNlg>
HCT116 M{G1dmZ2dmO2aX;uJGF{e2G7 NVXkeG01OTBizszN M1nzeVEzyqCqwrC= NILiPGJFVVOR MWnpcoNz\WG|ZYOgS2ZRNUyFM1KgdJVv[3Sj MojjNlU4OTVyMki=
HCT116 BAX BAK1 DKO MoTJSpVv[3Srb36gRZN{[Xl? NUDWe5pUOTBizszN MYCxNuKhcMLi M4TGWGROW09? NFize3ZqdmO{ZXHz[ZMhT0[SLVzDN2IheHWwY4Th MW[yOVcyPTB{OB?=
HCT116 NXzlXIhESXW2b4DoZYd6KEG|c3H5 MnS4NVAh|ryP Mmi1NVLDqGkEoB?= MX7EUXNQ MVrpcoR2[2W|IHGgZ49ueGyndHWgZZV1d3CqYXfpZ{Bz\XOyb37z[S=> MUGyOVcyPTB{OB?=
HCT116 BAX BAK1 DKO NXW2ZmdISXW2b4DoZYd6KEG|c3H5 MVKxNEDPxE1? NFnhd|cyOsLiaNMg MUHEUXNQ MmLYbY5lfWOnczDhJINwdXCuZYTlJIF2fG:yaHHnbYMhemW|cH;ud4U> NGjY[JgzPTdzNUCyPC=>
U937 NUi5dlg4SXCxcITvd4l{KEG|c3H5 NV6wbVB5OC5zMkWtNkDPxE1? M4TDTVI1KGh? MXzlcohidmOnczDETGEwYC1zMT3pcoR2[2WmIHHwc5B1d3Orcx?= MWmyOVcyPDB{NB?=
U937  NELXZo9CeG:ydH;zbZMhSXO|YYm= NYLlSmpqOC53IN88US=> MkTXNlQhcA>? NF25UlJmdmijbnPld{BkdGWjdnHn[UBw\iCSQWLQJIFv\CClYYPwZZNmNTNiYYOge4VtdCCjczDOc5hiKGyndnXs NUS3PVlEOjV5MUSwNlQ>
HL-60 AAA-Bcl-2 NYe0OnBHSXCxcITvd4l{KEG|c3H5 M1PGeVAuPSEQvF2= NVzBRnFuPDhiaB?= NF7NZVdKSzVyPUCuPFch|ryv78{MbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mk\uNlU4OTF2NkC=
HL-60 EEE-Bcl-2 M2PVNmFxd3C2b4Ppd{BCe3OjeR?= NHTRbJYxNTVizszN MoHVOFghcA>? M{DPbWlEPTB;NTFOwI3wxIxiaX7keYNmeyClZXzsJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M4raU|I2PzFzNE[w
U87 MWLGeY5kfGmxbjDBd5NigQ>? MVO1NEDPxE1? NX7hcG5ROjRiaB?= MYry[YR2[2W|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJG1OWC1{LDDNUXAuOTRiYX7kJGJkdC1{ NUizO|BSOjV4Nke2OlM>
K562 Mn\5R4VtdCCYaXHibYxqfHliQYPzZZk> MlLYNU0yOCEQvF2= NWTBUI5kPDhiaB?= NH3LeXRFVVOR MkTOTWM2OD1{Nj63JO69VQ>? NWrOZ5pOOjV3OU[1OlE>
K562/Mcl -1-IRESBim MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjMTWh1UUN3ME25MlMh|ryP NWLmOHVqOjV3M{W5NFA>
K562/Bcl- 2-IRESBim NVfkSGhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j2O2lEPTB;MD6zOUDPxE1? NHfzRYczPTV|NUmwNC=>
Jurkat NXXjO5Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\FTWM2OD1yLk[2JO69VQ>? MWSyOVU{PTlyMB?=
JurkatΔBak NUTPR4VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHyydW1KSzVyPkWwJO69VQ>? NWfhXm5ZOjV3M{W5NFA>
HL60/VCR NUH3VHdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvvUZY3UUN3ME6xNFAh|ryP MXqyOVU{PTlyMB?=
Kasumi-1 MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH71VI9KSzVyPUCuNFEh|ryP M{\DelI2PTN3OUCw
Kasumi-1/ABT MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHETWM2OD1yLkWxJO69VQ>? NXXWOVc1OjV3M{W5NFA>
THP-1 M4P0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLhTWM2OD1zLkK3JO69VQ>? M{XiOlI2PTN3OUCw
U937 NHi4TGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj3TWM2OD13LkK5JO69VQ>? Mo\xNlU2OzV7MEC=
C1498 MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDLdYV5UUN3ME22MlE{KM7:TR?= MlTXNlU2OzV7MEC=
RPMI 8226 NGT6SVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln0TWM2OD1yLkK1JO69VQ>? NEjZWIgzPTV|NUmwNC=>
MM.1S MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PET2lEPTB;MD60NEDPxE1? NHr4[XIzPTV|NUmwNC=>
NCI-H929 M2T3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv4TWM2OD1zNT6yNUDPxE1? NYjLPZE4OjV3M{W5NFA>
U266 M4XVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TRc2lEPTB;MD62PEDPxE1? MUWyOVU{PTlyMB?=
MCF-7 NVqwemFQS2WubDDWbYFjcWyrdImgRZN{[Xl? NYTaN4poPSEQvF2= M3:w[|Q5KGh? NYPLZ4FQTE2VTx?= NH3Ld3lmdmijbnPld{B1cGVic3Xud4l1cX[rdImgeI8hd3JicnHkbYF1cW:w M2W5UFI2PDB7MUK0
MCF-7 NX3rNVFwSXCxcITvd4l{KEG|c3H5 NWDqfmJ4PSEQvF2= NGC1Spk1NzJ2L{S4JIg> MVrEUXNQ MYPpcoNz\WG|ZYOgeIhmKGOuZXH2[YQhWEGUUB?= MVOyOVQxQTF{NB?=
MCF-7 NX;6SVlSTnWwY4Tpc44hSXO|YYm= Moq4OUDPxE1? NUHpN3lROjRiaB?= NEH4OGZFVVOR MnOx[Y5p[W6lZYOgeIhmdGW4ZXygc4YhVWOuLUGg[ZhxemW|c3nvcuKh NW\q[IpiOjV2MEmxNlQ>
MDA-MB 231  MXLGeY5kfGmxbjDBd5NigQ>? NX3TVVNpPSEQvF2= MlXXNlQhcA>? MX;EUXNQ NUjS[|V6\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi NHfld4ozPTRyOUGyOC=>
ZR-75-1  NX\zbGRYTnWwY4Tpc44hSXO|YYm= MoXqOUDPxE1? MmTFNlQhcA>? MmnvSG1UVw>? Mme3[Y5p[W6lZYOgeIhmdGW4ZXygc4YhVWOuLUGg[ZhxemW|c3nvcuKh NIK0e2ozPTRyOUGyOC=>
A549 Mn[zR4VtdCCYaXHibYxqfHliQYPzZZk> NEjHUIYxNTJyIN88US=> NELMU4o4OiCq M1H2eGROW09? MY\k[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv NHPsRlgzPTN6OEe2Ni=>
H1299 M2P4d2NmdGxiVnnhZoltcXS7IFHzd4F6 NFPzU5kxNTJyIN88US=> NFu2WFk4OiCq MXnEUXNQ M1TmPYRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? M1PiN|I2Ozh6N{[y
HO-8910 MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFiycG0xNTJyIN88US=> NHvOb4s4OiCq NVzvZXhsTE2VTx?= NUT5[5lQ\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= NVu4WXBZOjV|OEi3OlI>
HT-29 NYL4Z5VCS2WubDDWbYFjcWyrdImgRZN{[Xl? NFWwVFcxNTJyIN88US=> Mn:3O|IhcA>? MVLEUXNQ MlT0[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? M{foU|I2Ozh6N{[y
HCT-116 M{j2UGNmdGxiVnnhZoltcXS7IFHzd4F6 M33NbFAuOjBizszN MlnpO|IhcA>? MVHEUXNQ MXjk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYKgZ49u[mmwZXSge4l1cCCjc4Dpdolv MWqyOVM5QDd4Mh?=
A549 NY\FcFM3SXCxcITvd4l{KEG|c3H5 M3jmTFIxKM7:TR?= M{XDNlQ5KGh? M{i1bGROW09? M1nENolv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEBie3Crcnnu Mm[wNlU{QDh5NkK=
H1299 MnuwRZBweHSxc3nzJGF{e2G7 NGfNZ2QzOCEQvF2= MWq0PEBp NWLSO5FLTE2VTx?= MWHpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?= MnqzNlU{QDh5NkK=
Sc-1 M{PxdmNmdGxiVnnhZoltcXS7IFHzd4F6 MWSwMlAxODFvMTFOwG0> MlzMPVYhcA>? M3u0SIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWOyOVM4OzVyOB?=
OcI-LY18 NWPIVJhkS2WubDDWbYFjcWyrdImgRZN{[Xl? NY[5Rm5FOC5yMECxMVEh|ryP MkX0PVYhcA>? MYPk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MU[yOVM4OzVyOB?=
RL  NV\2OmJpS2WubDDWbYFjcWyrdImgRZN{[Xl? NIqyeJIxNjByMEGtNUDPxE1? M4TiUlk3KGh? MXjk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWGyOVM4OzVyOB?=
RKO MWnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4frSVAuOTBizszN NWX1bW9iOjUkgJnoxsA> NUjmWIpiTE2VTx?= MYrJR|UxRuLCiUK15qCKyrWP NFrtUJAzPTNyNEO4Ny=>
Caco-2 M2KwXGNmdGxiVnnhZoltcXS7IFHzd4F6 MV6wMVExKM7:TR?= MmnzNlTjiImqwrC= M4fMRWROW09? Mki1TWM2OD1zOT635qCKyrWP MnuzNlU{ODR|OEO=
DLD1 M3r6PGNmdGxiVnnhZoltcXS7IFHzd4F6 MnLuNE0yOCEQvF2= M2i5NVI16oDLaNMg MYTEUXNQ NHL2N3ZKSzVyPUG4Mlc56oDLwsXN NE[xT|AzPTNyNEO4Ny=>
LS411N M4TkSmNmdGxiVnnhZoltcXS7IFHzd4F6 NYn6VVRlOC1zMDFOwG0> M1;PR|I16oDLaNMg NXnmXXFkTE2VTx?= NXj3RoZrUUN3ME2xNU41P+LCidM1US=> MXeyOVMxPDN6Mx?=
SW620 MV;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkW3NE0yOCEQvF2= NYTseZBoOjUkgJnoxsA> MWTEUXNQ MmS4TWM2OD1zMj6yOQKBkcL3TR?= NF7TfIgzPTNyNEO4Ny=>
HCT116 Mn3OR4VtdCCYaXHibYxqfHliQYPzZZk> MUCwMVExKM7:TR?= NXXmUYl4OjUkgJnoxsA> M{\zTmROW09? NHq4ToRKSzVyPUKwMlQ66oDLwsXN MkTpNlU{ODR|OEO=
HaCaT M{PC[GNmdGxiVnnhZoltcXS7IFHzd4F6 Moq4NE4yNzFxMUCg{txO MmLmNlQhcA>? M2rLXmROW09? NVHwZWh4\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MlXyNlUzOTB5OUW=
A5-RT3 NYPC[lJCS2WubDDWbYFjcWyrdImgRZN{[Xl? NHr1cJIxNjFxMT:xNEDPxE1? NV\XW5RPOjRiaB?= MVzEUXNQ NYnmZYtS\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NH;I[2QzPTJzMEe5OS=>
HaCaT MnHpSpVv[3Srb36gRZN{[Xl? MWWxNQKBkc7:TR?= MUGyOE81QCCq MYnEUXNQ NXq5SHk1cW6mdXPld{BOVVBiYX7kJGRPSSCocnHncYVvfGG2aX;u MUOyOVIyODd7NR?=
A5-RT3 MonvSpVv[3Srb36gRZN{[Xl? M4PwXlEx6oDLzszN NXzEZ4M4OjRxNEigbC=> MVPEUXNQ NFuzUYtqdmS3Y3XzJG1OWCCjbnSgSG5CKG[{YXft[Y51[XSrb36= MUiyOVIyODd7NR?=
A5-RT3 M4fh[WZ2dmO2aX;uJGF{e2G7 M3fWTVUh|ryP MnjROkBp NYLyeIdTTE2VTx?= MUfpcoR2[2W|IITo[UBz\WynYYPlJI9nKG2rdH;jbI9v\HKrYXygdJJwfGWrboOgZY5lKHKnZIXj[ZMh[2yxbn;n[Y5q[yC|dYL2bZZidCCrbjDhJINie3Cjc3WtbY5l\XCnbnTlcpQhdWGwbnXy MYmyOVIyODd7NR?=
U266 MXHGeY5kfGmxbjDBd5NigQ>? MoLoOVAxNzd3MDDuUS=> M3foO|I1NzR6IHi= NETRWopFVVOR M3LGd4Rwf26{ZXf1cIF1\XNiQnntMEBxemmwY3nwZYxtgSC2aHWgSWwhcXOxZn;ycS=> MorJNlUzODh6OEi=
RPMI8226 M2LqOGZ2dmO2aX;uJGF{e2G7 NV[yNGVCPTByL{e1NEBvVQ>? NFzLUHAzPC92ODDo MlnYSG1UVw>? NUT3Sopz\G:5boLl[5Vt[XSnczDCbY0tKHC{aX7jbZBidGy7IITo[UBGVCCrc3;mc5Ju MlLYNlUzODh6OEi=
MM.1S M4DCUWZ2dmO2aX;uJGF{e2G7 MUW1NFAwPzVyIH7N MmrRNlQwPDhiaB?= NUHhVlFQTE2VTx?= MXrkc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2= NUXOZWZqOjV{MEi4PFg>
Clone A NWXyOHdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV2wMlLjiJN4MDFOwG0> NW\3VVliPzJiaB?= MWPEUXNQ NYHDUoo{UUN3ME23MlUh|ryP NHvkXJUzPTJyOEi4Ni=>
CX-1 Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOwMlLjiJN4MDFOwG0> MWO3NkBp MmKxSG1UVw>? NFTkVWNKSzVyPUGuPEDPxE1? M3fCO|I2OjB6OEiy
LS174T M2\kV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\hOFJ2OC5{4pETOlAh|ryP NFjHTJY4OiCq NIj6UI1FVVOR M2C4[WlEPTB;MUiuN{DPxE1? NYLuOoZWOjV{MEi4PFI>
HT29 NWrw[GhNSXCxcITvd4l{KEG|c3H5 NV3QOJlpOS93L{GwJO69VQ>? M{DkblQ5KGh? NET3UnRk[XW|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Ml[4NlUyQTJzOEi=
SW480 MmfRRZBweHSxc3nzJGF{e2G7 M2TPfVEwPS9zMDFOwG0> NVvNc3F3PDhiaB?= NXH3V4M2[2G3c3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MkH2NlUyQTJzOEi=
Colo205 NYK1dYhrSXCxcITvd4l{KEG|c3H5 NInhZ5QyNzVxMUCg{txO NWiwPHV[PDhiaB?= MXTjZZV{\XNiY3XscEBl\WG2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmjrNlUyQTJzOEi=
Caco2 NYexd4pDSXCxcITvd4l{KEG|c3H5 M4G2Z|EwPS9zMDFOwG0> NHTpflI1QCCq MljMZ4F2e2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MXmyOVE6OjF6OB?=
PCI-13 MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWe3NkBp MonZSG1UVw>? NFL3U2lIUTVyPUG1JOKyKDFwODFOwG0> M1P3cFI2OTN7M{i3
PCI-15B MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\KVXplPzJiaB?= M2XvbWROW09? MUHHTVUxRTFzINMxJFQvPSEQvF2= MVOyOVE{QTN6Nx?=
UM-SCC22B Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\ETGE4OiCq MVTEUXNQ NYnDZXJCT0l3ME2xPUDDuSB{Lkmg{txO MWqyOVE{QTN6Nx?=
UM-SCC47 M1i5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDBWZVzPzJiaB?= NWL6UGc{TE2VTx?= Mmn0S2k2OD1zOTFCtUAyOi5|IN88US=> M{\TO|I2OTN7M{i3
93-VU-147T Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7aSFQ3PzJiaB?= M{Sze2ROW09? MojWS2k2OD12LkOgxtEhOy53IN88US=> MmPBNlUyOzl|OEe=
UD-SCC2 Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTnWow4OiCq NEHtc2pFVVOR M2nycGdKPTB;MkigxtEhOi57IN88US=> NEKyVJYzPTF|OUO4Oy=>
UPCI:SCC90 NGHr[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzpO|IhcA>? NIHtSnJFVVOR MYTHTVUxRTZwNjFCtUAyNjVizszN NYDkSIpZOjVzM{mzPFc>
RPMI-8226  M3[xfWNmdGxiVnnhZoltcXS7IFHzd4F6 MXixNlUwOjVyL{WwNEBvVQ>? NXzMVHFiPDiqwrC= MnPmSG1UVw>? NWe5doRD\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmTGNlUxODh{MEK=
OPM-2  NXnZdlJ7S2WubDDWbYFjcWyrdImgRZN{[Xl? NEHPVmkyOjVxMkWwM|UxOCCwTR?= NHfMfYQ1QGkEoB?= NYHlUWFrTE2VTx?= MoHi[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3KzTFI2ODB6MkCy
RPMI-8226  NV;qUGF6SXCxcITvd4l{KEG|c3H5 M{XBOlEzPS9{NUCvOVAxKG6P NWj3botRPDiqwrC= M4TWNGROW09? Mn64bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MW[yOVAxQDJyMh?=
OPM-2  NI\nPXRCeG:ydH;zbZMhSXO|YYm= NUK4b4dROTJ3L{K1NE82ODBibl2= MV[0PIjDqA>? M1LJNGROW09? MUjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmLPNlUxODh{MEK=
COG-LL-319 MWnGeY5kfGmxbjDBd5NigQ>? M17BVFExOCCwTR?= MWGxM|MwPiCq Mk\XSG1UVw>? NXLKT|hUcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBO[2xvMTDjcIVifmGpZR?= MViyOFk2OTR5Mh?=
RS4;11 MU\GeY5kfGmxbjDBd5NigQ>? M1rtOlExOCCwTR?= MUSxM|MwPiCq MoHMSG1UVw>? M3nt[Ilv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgUYNtNTFiY3zlZZZi\2V? MnToNlQ6PTF2N{K=

... Click to View More Cell Line Experimental Data

体内研究 ABT-737按30 mg/kg剂量作用于白血病模型,抑制白血病负担值达53% , 且明显延长鼠寿命。ABT-737不会引起血细胞数和血浆化学性质发生变话。[1] ABT-737延长移植BCL-2传感肿瘤的鼠寿命。[2] ABT-737按100 mg/kg剂量作用于ATLL鼠模型具有强抗癌活性。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

荧光偏振实验:

测定GST-BCL-2蛋白家族与FITC-BIM BH3域结合的亲和力。100 nM GST-BCL-2家族融合蛋白和不同浓度 ABT-737在PBS温育2分钟。然后,加入20 nM FITC-BIM BH3 肽。进行荧光偏振,测定IC50值。
细胞实验:

[4]

+ 展开
  • Cell lines: SCLC细胞系,包括NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR,和DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48小时
  • Method:

    SCLC细胞在含10%人血浆的 100 μL 组织培养基的96孔培养板上处理48小时,使用MTS测定存活细胞。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 注射ER细胞的Scid 鼠
  • Formulation: 30% 丙二醇, 5% Tween-80, 65% D5W (5% 葡萄糖水溶液) (pH 4−5)
  • Dosages: 20 mg/kg和30 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% Propylene glycol, 5% Tween 80, 65% D5W
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 813.43
化学式

C42H45ClN6O5S2

CAS号 852808-04-9
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • 回答:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

相关Bcl-2产品

Tags: 购买ABT-737 | ABT-737供应商 | 采购ABT-737 | ABT-737价格 | ABT-737生产 | 订购ABT-737 | ABT-737代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID